Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended sacituzumab govitecan for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The decision was based on the unfavourable cost effectiveness of sacituzumab govitecan compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for sacituzumab govitecan are provided in the Annex.

Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer (17 Feb 2025) [PDF, 218 KB]

PES Sacituzumab govitecan for previously treated HR-positive, HER2-negative advanced breast cancer (17 Feb 2025) [PDF, 96 KB]